BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
6/23/2022 2:39:01 PM | Browse: 777 | Download: 2004
 |
Received |
|
2021-08-08 06:55 |
|
Peer-Review Started |
|
2021-08-08 06:59 |
|
First Decision by Editorial Office Director |
|
2021-11-11 08:37 |
|
Return for Revision |
|
2021-11-11 08:37 |
|
Revised |
|
2021-11-18 15:15 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2022-05-24 03:20 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2022-05-28 07:15 |
|
Articles in Press |
|
2022-05-28 07:15 |
|
Edit the Manuscript by Language Editor |
|
2022-04-23 11:44 |
|
Typeset the Manuscript |
|
2022-05-30 09:21 |
|
Publish the Manuscript Online |
|
2022-06-23 14:39 |
| ISSN |
1948-5182 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Meta-Analysis |
| Article Title |
Efficacy and safety of sofosbuvir/velpatasvir with or without ribavirin in hepatitis C genotype 3 compensated cirrhosis: A meta-analysis
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Jing Hong Loo, Wen Xin Flora Xu, Jun Teck Low, Wei Xuan Tay, Le Shaun Ang, Yew Chong Tam, Prem Harichander Thurairajah, Rahul Kumar and Yu Jun Wong |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| Nurturing Clinician Scientist Scheme (NCCS) award by SingHealth Duke-NUS Academic Medical Centre and National Medical Research Council Singapore |
|
|
| Corresponding Author |
Yu Jun Wong, FRCP, MD, Consultant Physician-Scientist, Department of Gastroenterology and Hepatology, Changi General Hospital, Singhealth, 2, Simei Street 3, Singapore 529889, Singapore. eugene.wong.y.j@singhealth.com.sg |
| Key Words |
Direct-acting antiviral; Hepatitis C; Cirrhosis; Sofosbuvir/velpatasvir |
| Core Tip |
Ribavirin (RBV) as routine add-on therapy was not associated with higher sustained virological response in genotype 3 (GT3) compensated cirrhosis patients receiving sofosbuvir/velpatasvir (SOF/VEL), except in the subgroup of patients with baseline resistance-associated substitution mutation. As RBV is associated with a higher risk of treatment-related adverse event, RBV as routine add-on therapy to SOF/VEL should be reconsidered among compensated GT3 cirrhosis patients. |
| Publish Date |
2022-06-23 14:39 |
| Citation |
Loo JH, Xu WXF, Low JT, Tay WX, Ang LS, Tam YC, Thurairajah PH, Kumar R, Wong YJ. Efficacy and safety of sofosbuvir/velpatasvir with or without ribavirin in hepatitis C genotype 3 compensated cirrhosis: A meta-analysis. World J Hepatol 2022; 14(6): 1248-1257 |
| URL |
https://www.wjgnet.com/1948-5182/full/v14/i6/1248.htm |
| DOI |
https://dx.doi.org/10.4254/wjh.v14.i6.1248 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
